Roche MS Pill Receives FDA Priority Review for Accelerated Approval

Key Facts

1Roche's multiple sclerosis pill has been granted priority review by the U.S. Food and Drug Administration.

Roche's multiple sclerosis pill has been granted priority review by the U.S. Food and Drug Administration. Seeking Alpha reported that the FDA granted this status to the marketing application for the oral medication developed by the company's Genentech unit. Priority review is typically reserved for treatments that offer significant improvements in the safety or effectiveness of diagnosing or treating serious conditions.

RHHVF closed at $431.56 on September 29, 2026, with the stock reaching a session high of $431.56 and a low of $413. This regulatory milestone represents a positive development for the large-cap pharmaceutical firm, though final market approval for the drug remains pending.